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Abstract
Introduction—About 10% of tumors derived from nongynecologic, noncoelomic tissues react 
with the OC125 antibody. Some patients with advanced prostate cancer were found to have 
elevated serum CA-125 level.
Materials and Methods—We examined the clinical history of 11 patients with castration-
resistant prostate cancer and an elevated serum CA-125 level. Pathological review and 
immunohistochemical staining were performed on tumors from 8 of these patients.
Results—Patients with advanced prostate cancer and an elevated serum CA-125 level responded 
to androgen ablative therapy (median duration, 27 months). They were predisposed to develop 
persistent or recurrent urinary symptoms and visceral metastases. Eight of 11 patients had a low or 
undetectable serum prostate-specific antigen level (≤4 ng/ml) or an elevated serum 
carcinoembryonic antigen level (>6 ng/ml). In 3 of 7 patients whose specimens were available for 
further review, the tumors contained histologic features compatible with a diagnosis of ductal or 
endometrioid adenocarcinoma of the prostate.
Conclusions—Patients with prostate cancer and an elevated serum CA-125 level have unique 
clinical and pathologic characteristics. Some of these patients possess tumors compatible with a 
subtype of prostate cancer known as ductal adenocarcinoma. Additional studies need to be 
performed to elucidate the biologic basis of the various subtypes of prostate cancer.
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INTRODUCTION
It seems paradoxical that a masculine disease like prostate cancer may be associated with a 
feminine biomarker like CA-125. However, another male-exclusive malignancy, namely 
seminal vesicle carcinoma, has also been found to produce CA-125.1 In fact, about 28% of 
patients with nongynecologic tumors have elevated serum CA-125 levels and 10% of tumors 
derived from nongynecologic, noncoelomic tissues react with the OC125 antibody.2 To our 
knowledge, there is only one other report that described CA-125 expression in prostate 
cancer.3 Since prostate cancer normally metastasize to the pelvic-retroperitoneal lymph 
nodes and to the bones rather than to the coelomic structures, such as the pleura or 
peritoneum, it is presumed that the cancer cells themselves produce CA-125.
This study was prompted by a serendipitous observation that serum CA-125 level was 
elevated in some patients with castration-resistant prostate cancer. Further investigation 
revealed that several of these patients contained tumors with pathological features consistent 
with a diagnosis of ductal or endometrioid adenocarcinoma of the prostate.4–12 These 
patients had unique clinical presentations such as intractable urinary symptoms and atypical 
visceral metastases after hormonal ablative therapy. Since not all ductal adenocarcinomas 
produce an elevated CA-125 level, we postulate that there may be different subtypes of 
prostate ductal adenocarcinoma. A distinct subtype of ductal adenocarcinoma may be 
associated with increased serum CA-125 level. We report the clinical characteristics and 
pathological findings of 11 patients with advanced prostate carcinoma and an elevated 
serum CA-125 level (>35 ng/ml).
MATERIALS AND METHODS
Clinical Data
Between December 1, 1998 and April 1, 1999, we measured at least one serum CA-125 
level in 55 non-consecutive patients with castration-resistant prostate cancer. These patients 
were either referred for evaluation of progression of disease or followed for evidence of 
progression of disease (i.e., increasing serum PSA, or worsening clinical symptoms) by one 
of the authors (ST) in the Genitourinary Medical Oncology Clinic at The University of 
Texas M. D. Anderson Cancer Center. Eleven patients were found to have an elevated serum 
Ca-125 level (>35 ng/ml) and were selected for further studies (Table 1). Patients with 
evidence of pleural, pericardial, or peritoneal metastases were excluded. The clinical history, 
cystoscopic findings, laboratory results, and treatment effects were obtained from patient 
charts and from the computer data management system of the M. D. Anderson Cancer 
Center. Survival of patients was measured from the time of diagnosis and androgen ablative 
therapy until death from any cause or last follow-up visit.
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Eight tissue blocks from 7 of the 11 patients were available for the study (Table 2). Two 
specimens were obtained from a transurethral resection of the bladder, 3 from biopsy of the 
prostate, 2 from biopsy of recurrent tumor at the prostate anastomotic site, and one from a 
cystoprostatectomy. Some specimens were procured from the same patients before and after 
androgen ablative therapy. Six samples of fine-needle biopsies of metastases to the liver, 
lung, adrenal, and pancreas from 5 of the 11 patients were also available for examination. 
We performed immunohistochemical studies (prostate-specific antigen [PSA], CA-125, and 
carcinoembryonic antigen [CEA]) on formalin-fixed, paraffin-embedded sections (4–5 μm 
thick) from each specimen. For each antibody, known tissue-positive controls and tumor 
sections were stained simultaneously.
Immunostaining
Commercially available antibody against OC 125 (Dako) (diluted 1:50 in 5% newborn calf 
serum in phosphate-buffered saline (NCS/PBS) was used to identify tumor cells highly 
expressive of the CA-125 antigen. Antibody against PSA (Biogenex, San Ramon CA) 
(dilution 1:100 in 5% NCS/PBS) and CEA (Dako, Carpinteria CA) (diluted 1:200 in 5% 
NCS/PBS) were used to evaluate PSA and CEA expression in the tumor specimens, 
respectively. The antibody 34βE12 (Dako) (diluted 1:50 in 5% NCS/PBS) was used as a 
marker for basal cells and to differentiate high-grade prostatic intraepithelial neoplasia from 
invasive carcinoma. All sections were deparaffinized and rehydrated. For immunostaining, 
sections were first washed in PBS, followed by quenching of endogenous peroxidases in the 
tissue by submerging the sections in 0.3% hydrogen peroxide in methanol. The antigens 
were then retrieved from all sections by consecutive microwave heatings of sections 
immersed in buffered citric acid, pH 6.0 (Citra Solution; Biogenex).
The streptavidin-biotin (ABC) method was used to detect each antibody probe. Materials 
from Vectastain immunodetection kits against either mouse or rabbit immunoglobulins were 
used for staining. Normal horse or goat serum was applied to the sections as a blocking 
agent and then removed before the appropriate primary antibody was applied. The sections 
were incubated in the primary antibody solution, then in a solution of biotinylated secondary 
antibodies against mouse or rabbit immunoglobulins, followed by a Vectastain avidin-
peroxidase fusion protein solution. The sections were subsequently developed for stain 
formation in hydrogen peroxide-diaminobenzidine solution. Immunostaining was scored 
according to the intensity of staining (1+ weak or 2+ strong) and the percentage of positively 
stained tumor cells (focal or diffuse).
RESULTS
Clinical Studies
Eleven out of 55 patients (20%) were found to have at least one elevated serum Ca-125 level 
(>35 ng/ml) during the 4 months period. The clinical characteristics of the 11 patients who 
had an elevated serum Ca-125 level were described in Table 3. The median age was 64 
years. The median survivals since diagnosis and androgen deprivation therapy were 113 and 
51 months, respectively. The duration of effective androgen deprivation therapy for these 
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patients was 27 months. Six of 8 patients who received cytotoxic chemotherapies responded 
to treatment based on palliative benefit, PSA or CEA decline, and/or radiographic 
improvement. Eight of 11 patients had a low or undetectable serum PSA level (≤4 ng/ml) or 
an elevated serum CEA level (>6 ng/ml). Eight of 11 patients developed liver or lung 
metastases. In addition, 3 patients developed bladder invasion, 2 patients had adrenal 
metastases, and one patient each had metastases to the brain, pancreas, and penis. Seven 
patients developed bone metastases, including one whose bone metastases were 
predominantly osteolytic and another whose only site of osseous metastasis was in the base 
of skull. Interestingly, the remaining four patients did not develop skeletal metastases.
Pathologic and immunohistochemical Studies
Eight specimens from 7 of the 11 patients were available for pathologic review (Table 2). 
Overall, 3 of 7 patients whose pathologic slides were available for review had a pathologic 
diagnosis consistent with ductal adenocarcinoma of the prostate. The tumors displayed a 
papillary and cribriform pattern. The papillary pattern showed papillary fronds with cells 
lining fibromuscular stalks. The tumor cells were pseudostratified with abundant cytoplasm 
and elongated nuclei. Prominent nucleoli were present. This papillary pattern also had areas 
of solid growth with numerous blood vessels. The cribriform areas were composed of back 
to back glands with classical cribriform architecture and the previously described cytology. 
Central comedo-necrosis was frequently associated with this pattern. Mitotic figures were 
easily identified. The Gleason score for 6 of the 7 specimens was 8 or greater. The Gleason 
score was not included in the report of 2 specimens. All analyzed specimens stained positive 
for PSA (Table 2). CA-125 was expressed in 1 tumor specimen (Figure 1) and in 1 of 5 
cytological specimens. The two patients whose tumor or cytological specimens stained 
positively for CA-125 had higher serum CA-125 levels (>150 ng/ml).
DISCUSSION
Results of this study suggest that CA-125 may be a useful biomarker to distinguish a 
specific subtype of prostate ductal adenocarcinoma. Ductal adenocarcinoma of the prostate 
appears to be a distinct pathologic entity with unique clinical and biologic features. Patients 
with prostate ductal adenocarcinoma and an elevated serum CA-125 level tend to pursue an 
indolent course in spite of harboring a high Gleason score tumor. They respond to androgen 
ablation and chemotherapy. They are predisposed to develop persistent local urinary 
symptoms and atypical visceral metastases after androgen ablative therapy. The finding that 
CA-125 is expressed in a particular subtype of prostate cancer may help to refine current 
diagnosis of prostate cancer. It supports the view that there is a unique origin for the 
different types of prostate cancer.13
OC 125 is a murine IgG1 monoclonal antibody raised against an ovarian carcinoma cell line 
derived from the ascites of a patient with serous cystadenocarcinoma.14 It recognizes an 
epitope on a molecule called Cancer Antigen 125 (CA-125). CA-125 is a differentiation 
antigen associated with the coelomic epithelium (i.e. mullerian epithelia, peritoneum, pleura, 
and pericardium) and almost all of its normal (i.e. ovary, fallopian tubes, endometrium, 
endocervix) and neoplastic derivatives (i.e. ovarian and endometrial carcinoma, 
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mesothelioma). Sometimes, OC 125 reactivity is also noted in normal breast ducts, 
bronchiolar epithelium, and colonic mucosal cells adjacent to the tumors.2 In fact, CA-125 
has been found expressed in the normal epithelium of the pancreas, colon, gall bladder, 
stomach, lung, and kidney.
Only 1% of apparently healthy individuals have elevated serum CA-125 levels. In contrast, 
82% of patients with confined ovarian cancer and 28% of patients with nongynecological 
tumors have elevated serum CA-125 levels.2 Most, if not all, of the latter patients are 
presumed to have serosal metastases. About 10% of tumors derived from nongynecologic, 
noncoelomic tissues react with the OC125 antibody.2 In non-pregnant women, CA-125 is 
believed to arise from 3 possible sources: the ovary, the endometrium, and the peritoneum.15 
In men, CA-125 could be produced from coelomic derivatives (e.g.. the peritoneum or the 
pleura) or a mullerian vestige. Since prostate cancer normally does not metastasize to the 
coelomic tissues, the prostate cancer cells that produce CA-125 may represent a mimicry of 
or is a derivative from a mullerian vestige.
Ductal adenocarcinoma of the prostate was first recognized as a variant of prostate 
carcinoma by Melicow in 1967.4 Pure ductal adenocarcinoma is rare and has an incidence of 
about 1% of all prostate carcinoma, whereas mixed ductal and acinar carcinoma comprises 
about 6% of all prostate carcinoma.5 Ductal adenocarcinoma has been described to be a 
more virulent form of prostate cancer by some reports7,10, but more indolent by others.11,12 
We previously reported pure ductal prostate adenocarcinoma tends to pursue an indolent 
clinical course and poses an increased risk for local recurrence.16 Currently, it is unclear 
whether ductal adenocarcinoma is a distinct biological and clinical entity compared to acinar 
carcinoma of the prostate.17 It is also unknown whether the different histological types (i.e. 
endometrioid, primary ductal, and secondary ductal) and patterns (i.e. papillary, cribriform, 
and solid) of prostate ductal adenocarcinoma have any biological, clinical, or prognostic 
significance. Elucidation of the biology of prostate ductal adenocarcinoma will help to 
resolve some of these issues.
The diagnosis of prostate ductal adenocarcinoma can be elusive and problematic. Currently, 
ductal adenocarcinoma is diagnosed based on histological and immunohistochemical 
criteria. Ductal adenocarcinoma is characterized by the presence of tall pseudostratified 
epithelial cells arranged in a papillary pattern arising from the veramontanum or the primary 
ducts in the prostatic urethra. A cribriform pattern with slit-like lumens is found deeper 
within the secondary ducts. However, it is difficult to discern ductal adenocarcinoma with a 
solid pattern from a poorly differentiated carcinoma of the prostate.18 Furthermore, half of 
the ductal adenocarcinomas may stain only focally or weakly for PSA or PAP.19 It is likely 
that many poorly differentiated carcinomas with negative PSA or PAP staining will not be 
recognized or reported as ductal adenocarcinomas. The discovery of specific biomarkers 
will be invaluable for the diagnosis of prostate ductal adenocarcinoma.
There is controversy surrounding the biological origin of prostate ductal adenocarcinomas. 
The idea that certain ductal adenocarcinomas have a mullerian origin is based on the 
observation that they tend to arise in the middle lobe or the central zone of the prostate.20 It 
is hypothesized that the middle lobe has a distinct embryological origin compared to the rest 
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of the prostate. Here, in the vicinity of the prostatic utricle, there is an intermingling of 
mesodermal cells derived from the mullerian-wolffian ducts with endodermal cells 
originated from the urogenital sinus.21 In contrast, acinar carcinoma of the prostate 
originates from the urogenital sinus. Perhaps, a CA-125 producing prostate cancer merely 
reflects its coelomic identity rather than its mullerian-wolffian origin. Unfortunately, the 
kinetics of Ca-125 during disease progression or treatment could not be assessed due to the 
retrospective nature of this study. And important questions about the underlying biology of 
its regulation by androgen receptor or other molecules, secretion of Ca-125 into the blood 
stream, remain unanswered. Nevertheless, CA-125 may be a useful biomarker that 
distinguishes ductal from acinar carcinomas of the prostate and alludes to the presence of a 
specific subtype of prostate ductal adenocarcinoma.
A closer examination of the clinical characteristics of the 11 patients in this study revealed 
some interesting observations. The patients responded adequately to androgen deprivation 
therapy (27 months). A majority also responded to some types of chemotherapy. They had a 
relatively prolonged survival of 57 months after androgen deprivation therapy and 113 
months after diagnosis, considering that most of them (6 of 8) had high Gleason scores (8 – 
10) at the time of diagnosis (3 patients) or during subsequent biopsies (3 patients). Eight 
patients had either a low or undetectable serum PSA or elevated CEA levels. There was an 
increased incidence of atypical visceral metastases in the liver, lungs, adrenals, pancreas, 
brain, and penis. Furthermore, a large proportion of the patients either did not develop bone 
metastases (4 patients) or had focal or late-onset osseous metastases (2 patients). The tumor 
tended to invade into the bladder causing gross hematuria and/or urinary obstructive 
symptoms requiring TURP and catherization (e.g. percutaneous nephrostomy, suprapubic). 
For this reason, several patients (6 of 11) underwent a salvage prostatectomy or 
cystoprostatectomy.
CONCLUSIONS
We described the pathologic features and clinical characteristics of patients with prostate 
cancer and elevated serum CA-125 level. The clinical characteristics indicated that these 
patients might pursue an indolent course in spite of an aggressive (i.e., high Gleason score) 
tumor. They responded to androgen ablation and chemotherapy. They appeared to be 
susceptible to persistent local urinary symptoms and atypical visceral metastases after 
androgen ablative therapy. The pathologic features of some of the tumors were compatible 
with a diagnosis of ductal or endometrioid adenocarcinoma of the prostate. Results of this 
study suggest that ductal adenocarcinoma is a distinct clinical and biologic entity. CA-125 
may be a useful biomarker for refining the diagnosis of prostate cancer in general and of 
prostate ductal adenocarcinoma in particular. The results need to be confirmed in another 
database or in a prospective clinical trial.
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The immunohistochemical staining pattern of CA-125 expression in human prostate tumor 
from patient#7.
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